Axios · Katherine Davis ·

Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025

Precision oncology biotech Pathos AI said Friday it raised a $237 million Series E round at a $3 billion post-money valuation.

AI Venture Capital

In this story Pathos AI

Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025

Lead Source

Axios — Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025 ↗

How this story grew

Coverage · 0 Discussion · 0

Oct 23Oct 24

More

Reuters: Reuters

Dow Jones Newswires: Dow Jones Newswires

STAT: STAT

Discussion

Related stories

TechCrunch: Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago

Fortune: EliseAI, which provides AI tools for health care and housing industries, raised $350M at a $4B valuation, up from $2.2B after raising $250M in August 2025

Axios: Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, raised a $25M Series A

Forbes: AI training data startup Micro1 raised $100M+ at a $4B valuation, up from $500M in September 2025; two frontier AI labs and xAI co-founders invested

Bloomberg: AI coding startup Cognition raised $2B at a $48B valuation, up from $26B in May, and says its run-rate revenue grew from $492M in May to ~$900M

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif